Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Opinion|Videos|February 4, 2026
Amy Luckenbaugh, MD, reflects on patient resilience, GU oncology advances for World Cancer Day
Author(s)Amy N. Luckenbaugh, MD
Fact checked by: Hannah Clarke
Amy N. Luckenbaugh, MD, FACS, shares what her patients have taught her about resilience as well as some of the advances in urologic oncology that are giving her hope.
Advertisement
In recognition of World Cancer Day on February 4, 2026, Amy N. Luckenbaugh, MD, FACS, shares what her patients have taught her about resilience as well as some of the advances in urologic oncology that are giving her hope. Luckenbaugh is a urologic oncology at Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Related to this article
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
4
Daniel Heng, MD, highlights final LITESPARK-011 results in advanced ccRCC
5